TITLE

Evotec's MAO-B Inhibitor Fails in Phase II Trial

PUB. DATE
April 2009
SOURCE
Bioworld Week;4/20/2009, Vol. 17 Issue 16, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the result of the Phase II clinical trial of smoking cessation drug called EVT 302 that failed to show improvement in the quit rate of smokers, and reassesses the manufacturer Evotec AG plans to reassess the drug following further analysis. EVT 302, a monoamine oxidase B inhibitor, failed to show any significant benefit when combined with a nicotine replacement patch compared to nicotine replacement therapy alone.
ACCESSION #
38213823

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics